Loading...
XPAR
TNG
Market cap81mUSD
May 22, Last price  
0.56EUR
1D
-2.09%
1Q
-21.40%
Jan 2017
-78.49%
Name

Transgene SA

Chart & Performance

D1W1MN
P/E
—
P/S
234.03
EPS
—
Div Yield, %
—
Shrs. gr., 5y
3.97%
Rev. gr., 5y
-45.94%
Revenues
307k
-74.07%
2,514,0005,546,00028,019,00013,949,00011,765,00014,112,00014,446,0003,928,0003,849,0002,490,0001,465,0002,346,0002,099,0001,335,0006,652,0002,981,0009,993,0003,126,0001,184,000307,000
Net income
-34m
L+52.15%
-20,485,000-22,031,000-5,521,000-18,000,000-27,347,000-34,219,000-43,626,000-43,203,000-42,858,000-48,556,000-46,374,000-25,207,000-32,274,0008,026,000-21,360,000-18,450,000-20,004,000-32,810,000-22,328,000-33,971,000
CFO
-24m
L-32.08%
-19,109,000-19,538,000-2,073,000-23,387,000-18,720,000-24,929,000-44,162,000-51,294,000-50,185,000-54,236,000-45,152,000-33,585,000-35,370,000-28,381,000-22,413,000-28,742,000-31,943,000-20,303,000-34,671,000-23,548,000
Earnings
Sep 22, 2025

Profile

Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. It is involved in developing TG4050, a therapeutic vaccine that is in phase I clinical trial for the treatment of ovarian cancer, and human papilloma virus (HPV)-negative head and neck cancers; TG4001, a therapeutic vaccine, which is in phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in phase I/IIa clinical trial for the treatment of various solid tumors, such as gastrointestinal adenocarcinoma comprising stomach, pancreas, and colon; and BT-001, an oncolytic virus, which is in phase I/II clinical trial for the treatment of solid tumors. The company also develops TG1050, a therapeutic vaccine for the treatment of chronic hepatitis B; and Pexa-Vec, an oncolytic virus for the treatment of solid tumors. It has strategic collaboration agreements with AstraZeneca, Merck KGaA, Pfizer, PersonGen BioTherapeutics, and NEC Corporation; licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva; and agreements with Sanofi, BioInvent, and Randox. The company was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.
URL
https://www.transgene.fr
IPO date
Mar 25, 1998
Employees
146
Domiciled in
FR
Incorporated in
FR

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
307
-74.07%
1,184
-62.12%
3,126
-68.72%
Cost of revenue
34,282
62,994
67,557
Unusual Expense (Income)
NOPBT
(33,975)
(61,810)
(64,431)
NOPBT Margin
Operating Taxes
(6,450)
6
Tax Rate
NOPAT
(33,975)
(55,360)
(64,437)
Net income
(33,971)
52.15%
(22,328)
-31.95%
(32,810)
64.02%
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
1,240
1,192
Long-term debt
1,274
3,706
Deferred revenue
23
Other long-term liabilities
12,986
19,546
14,533
Net debt
(16,670)
(14,499)
(1,178)
Cash flow
Cash from operating activities
(23,548)
(34,671)
(20,303)
CAPEX
(3,075)
(2,746)
(1,535)
Cash from investing activities
(3,206)
34,572
20,272
Cash from financing activities
26,959
11,369
(1,477)
FCF
(35,954)
(48,407)
(72,409)
Balance
Cash
16,670
15,666
26,826
Long term investments
1,347
(20,750)
Excess cash
16,655
16,954
5,920
Stockholders' equity
(73,584)
(55,334)
(32,972)
Invested Capital
101,774
91,749
84,210
ROIC
ROCE
EV
Common stock shares outstanding
100,957
100,590
99,502
Price
Market cap
EV
EBITDA
(32,694)
(60,238)
(62,745)
EV/EBITDA
Interest
168
804
Interest/NOPBT